Skip to main content
Category

News Archive

https___cdn.evbuc.com_images_55910079_290453431737_1_original.jpg

2-28 SBIR & Non-Dilutive Funding Workshop Agenda Set!

By News Archive

https___cdn.evbuc.com_images_55910079_290453431737_1_original.jpg

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW:  https://tinyurl.com/BHISBIR2019

  • 8:00 a.m. – Networking and Registration
  • 8:30 a.m. – Welcome
  • 8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
    • National Heart, Lung, and Blood Institute
    • National Institute on Aging
    • National Institute on Drug Abuse
    • National Cancer Institute  
  • 9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab  
  • 10:00 a.m. – BREAK
  • 10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation    
  • 11:00 a.m. – BREAK  
  • 11:15 a.m. – SBIR Funding Opportunities with USAMRC    
  • 11:45 a.m. –  Lunch  
  • 12:45 p.m. – (1:1 Room Set)  
  • 1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)  
  • 1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)  
  • 2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)  
  • 2:30 p.m. –  Writing Your Phase II Commercialization Plan  OR 1:1 Meetings* (available simultaneously))  
  • 3:00 p.m. –  1:1 Meetings* (NIH only)  
  • 4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019
No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

rock-health-logo

Beyond Wellness For the Healthy: Digital Health Consumer Adoption 2018 – Rock Health

By News Archive

rock-health-logo

Utilization of digital health services and technologies has been on the rise since we first began surveying the US adult population in 2015. Budding choices of wearables, apps, telemedicine, and other tech-enabled services make it easy for consumers to test out what it might be like to “go digital” for their health. In the first three years, our annual survey showed that tools for fitness and wellness represented a common (and low-risk) entry point for consumers to experiment with products that fit neatly into their already tech-enabled lifestyles. In the 2018 data that we examined for this report, we saw something different.

Read More
pitch-masters-logo

PitchMasters™ hosts four emerging startups at January event, expands to Baltimore and New York – Shulman Rogers

By News Archive

pitch-masters-logo

PitchMasters™, a workshop-style event for entrepreneurs preparing for their first institutional capital raise, held its 2019 Kick Off and Alumni Event on Jan. 30, 2019. Four emerging startup companies, Skipiit, Trove Therapeutics, Uplift and VERALOX Therapeutics, practiced their pitching skills and gained insights from experienced entrepreneurs, investors, industry influencers and fellow PitchMasters™ alumni.

Read More
brian-darmody-aurp-image

Brian Darmody Announced as AURP CEO & Launches ‘AURP HQ2’ in Washington, DC Area

By News Archive

brian-darmody-aurp-image

The Association of University Research Parks (AURP), a professional association of university-related research and science parks, announced the appointment of Brian Darmody, Associate Vice President of Corporate Engagement at the University of Maryland (UMD), as its new Chief Executive Officer (CEO). Additionally, the association has opened a new office at the UMD Discovery District in the Washington, DC area, to be known as ‘AURP HQ2.’ Mr. Darmody will immediately assume his new role as CEO at the new location. He will continue his role at UMD and plans to transition out of UMD over time.

Read More
704-qo-graph-image

New Lab Space Designed to Attract Biotech Talent and Community Opens at 704 Quince Orchard – BioBuzz

By News Archive

704-qo-graph-image

When construction is completed this month, 704 QO will offer ready-to-occupy lab/office spaces for companies of all sizes. What really makes this new building stand out isn’t just the fully customizable individual lab units, but the suite of amenities that are tailored to the specific needs of emerging life science companies in the BioHealth Capital Region and the employees that work for them. 

Read More
iqvia-logo

IQVIA Launches IQVIA Biotech, Dedicated to Emerging Biotech and Biopharma Industry

By News Archive

iqvia-logo

IQVIA™ (NYSE:IQV) today announced the launch of IQVIA™ Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies. This solutions suite, supported by more than 1,000 dedicated employees, will deliver simplified operating procedures, specialized teams, and services to provide a more agile way for these innovators to reach their drug development and commercialization milestones. From initial planning to trial design and implementation to market launch and commercialization, IQVIA Biotech delivers a transparent and streamlined process with a deep foundation in science.

Read More
astrazeneca-logo

US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

By News Archive

astrazeneca-logo

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV.

Read More
vlp-therapeutics-logo

VLP Therapeutics to Initiate First Clinical Trial of VLPM01 Malaria Vaccine

By News Archive

vlp-therapeutics-logo

VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. The Phase I/IIa clinical trial will begin recruiting participants in February 2019, and is designed to assess the safety, immunogenicity and efficacy of the VLPM01 vaccine. The clinical trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, MD.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.